Review
Immunology
Weidong Zhang, Ling Gao, Wenhao Ren, Shaoming Li, Jingjing Zheng, Shasha Li, Chunmiao Jiang, Shuying Yang, Keqian Zhi
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect, with hypotheses involving reduced bone remodeling, infection, inflammation, and bisphosphonates-induced immune dysfunction. Treatment with bisphosphonates disrupts mucosal and osteo immune homeostasis, impairing the body's ability to resist infection and repair from injury, contributing to the development of MRONJ.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Wen Pan, Jianyu Gu, Shihan Xu, Chunmei Zhang, Jinsong Wang, Songlin Wang, Junji Xu
Summary: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication in patients with osteoporosis or metastatic bone cancer. The study found that dietary nitrate, abundant in green vegetables, can protect against BRONJ-like lesions in mice. Nitrate intake increased plasma nitric oxide levels, reducing monocyte necrosis and inflammatory cytokine production. The findings suggest that dietary nitrate can inhibit monocyte necroptosis in BRONJ and promote bone remodeling after injury.
CELL PROLIFERATION
(2023)
Article
Medicine, General & Internal
Gabor Kammerhofer, Daniel Vegh, Dorottya Banyai, Adam Vegh, Arpad Joob-Fancsaly, Peter Hermann, Zoltan Geczi, Tamas Hegedus, Kata Sara Somogyi, Bulcsu Bencze, Zita Biczo, Donat Huba Juhasz, Peter Zaborszky, Marta Ujpal, Mihaly Tamas Vaszilko, Zsolt Nemeth
Summary: This study aimed to evaluate the association between hyperglycemia and medication-related osteonecrosis of the jaw (MRONJ). The results showed a significant association between hyperglycemia and MRONJ, suggesting that hyperglycemia may lead to vascular anomaly and immune dysfunction, resulting in necrosis after tooth extraction.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Chemistry, Multidisciplinary
Krzysztof Wrobel, Maciej Sikora, Maciej Checinski, Maria Jas, Dariusz Chlubek
Summary: MRONJ is a condition that is becoming more common in dental and maxillofacial practice, requiring comprehensive, accessible, and up-to-date data. Besides bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies can also increase the risk of the disease. Thorough physical examination, periodic correction of dental prostheses, and adequate preparation for oral procedures can prevent or minimize the risk of MRONJ.
APPLIED SCIENCES-BASEL
(2021)
Article
Oncology
Hironobu Hata, Kenji Imamachi, Michihiro Ueda, Masashi Matsuzaka, Hiroaki Hiraga, Toshihisa Osanai, Toru Harabayashi, Katsuya Fujimoto, Satoshi Oizumi, Masato Takahashi, Kazuhito Yoshikawa, Jun Sato, Yutaka Yamazaki, Yoshimasa Kitagawa
Summary: The study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid for different types of cancer. The results showed that patients with shorter survival times did not develop MRONJ, and dentists need to be aware of prognosis-related factors to predict MRONJ risk for effective dental management planning.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Dentistry, Oral Surgery & Medicine
Alexander Wick, Philipp Bankosegger, Sven Otto, Bettina Hohlweg-Majert, Timm Steiner, Florian Probst, Oliver Ristow, Christoph Pautke
Summary: This study identified several risk factors significantly increasing the onset of MRONJ in patients treated with DNO, including chemotherapy/hormonal therapy, DNO dosage, breast cancer, corticosteroid intake, hypertension, diabetes mellitus, periodontal disease, apical ostitis, and denture use. Switching medications did not affect the development of MRONJ.
CLINICAL ORAL INVESTIGATIONS
(2022)
Article
Multidisciplinary Sciences
Milad Etemadi Sh, Farnaz Shooshtarian, Golnaz Tajmiri, MohammadSoroush Sehat
Summary: The present experiment aimed to assess the preventive effects of L-PRF on osteonecrosis of the jaw in rats. The application of L-PRF resulted in a significant reduction in osteonecrosis centers and the number of osteoclast cells. Therefore, it can be inferred that possible preventive effects on the clinical occurrence of osteonecrosis could be expected from the application of L-PRF.
Article
Endocrinology & Metabolism
Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard, Benoit Schaller, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This study aimed to determine the risk of ONJ in a real-world population, showing a higher incidence rate in patients receiving denosumab therapy compared to those receiving BPs, with previous BP therapy potentially being an additional risk factor for ONJ development.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Toxicology
Bhumrapee Srivichit, Chanisa Thonusin, Nipon Chattipakorn, Siriporn C. Chattipakorn
Summary: Bisphosphonates are commonly used in the treatment of bone and joint diseases, but long-term use can lead to osteonecrosis. Osteonecrosis is characterized by cell death and impaired cell functions, with medication-related osteonecrosis of the jaw being the most concerning condition. In addition to surgical treatment, non-surgical interventions have been explored to mitigate bisphosphonate-induced osteonecrosis.
ARCHIVES OF TOXICOLOGY
(2022)
Article
Medicine, General & Internal
Songmi Kim, Seyoung Mun, Wonseok Shin, Kyudong Han, Moon-Young Kim
Summary: Genetic variants associated with MRONJ were identified through whole-exome sequencing, with genes enriched for keratinization and calcium ion transport functions. Key genes related to MRONJ may include KRT18 and PABPC3.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Xiao-Hong Wu, Shi-Wei Chen
Summary: This report presents a case of multiple myeloma (MM) identified in a surgical specimen previously diagnosed as medication-related osteonecrosis of the jaw (MRONJ) in a patient with MM. The patient exhibited symptoms of both MRONJ and MM, suggesting that MM and MRONJ can occur simultaneously at the same site.
Review
Endocrinology & Metabolism
Athanasios D. Anastasilakis, Jessica Pepe, Nicola Napoli, Andrea Palermo, Christos Magopoulos, Aliya A. Khan, M. Carola Zillikens, Jean-Jacques Body
Summary: This study evaluates the differences of MRONJ among different patient categories and provides recommendations on how to mitigate the risk and optimally manage MRONJ. The results indicate that patients with advanced malignancies are at a higher risk for MRONJ compared to those with benign bone diseases, but the overall risk is considerably lower than the benefits of treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Dentistry, Oral Surgery & Medicine
Jie Liu, Nikos Mattheos, Chuanxi Deng, Cheng Su, Zekun Wang, Nanyu Luo, Hua Tang
Summary: Icariin benefits MRONJ by improving soft tissue wound area and empty bone lacuna ratio, while teriparatide activates RANKL expression and reduces bone necrosis area and empty lacuna ratio. These findings suggest potential therapeutic benefits for patients with MRONJ.
JOURNAL OF PERIODONTOLOGY
(2021)
Article
Endocrinology & Metabolism
Se Hwa Kim, Young-Kyun Lee, Tae-Young Kim, Yong-Chan Ha, Sunmee Jang, Ha Young Kim
Summary: The study aimed to estimate the incidence of osteonecrosis of the jaw (ONJ) in Korean osteoporosis patients treated with bisphosphonates (BPs) and identified clinical risk factors such as advanced age, diabetes, and rheumatoid arthritis that increase the risk for ONJ.
Article
Dentistry, Oral Surgery & Medicine
Isabel Pennings, Alison Moskowitz, Gunjan Shah, Cherry Estilo, Joseph M. Huryn, SaeHee K. Yom
Summary: We report a case of osteonecrosis of the jaw (ONJ) associated with pembrolizumab, a rare yet potentially emerging complication. The temporal relationship and treatment regimen suggest an association between pembrolizumab/GVD therapy and ONJ development, with the possibility of thrombocytosis and anatomical factors playing a role. As the use of pembrolizumab is expected to increase, documenting such cases is important for informing dental treatment in cancer patients undergoing pembrolizumab therapy.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
(2023)
Article
Oncology
Marina Carpano, Marina Perona, Carla Rodriguez, Susana Nievas, Maria Olivera, Gustavo A. Santa Cruz, Daniel Brandizzi, Romulo Cabrini, Mario Pisarev, Guillermo Juan Juvenal, Maria Alejandra Dagrosa
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2015)
Article
Chemistry, Inorganic & Nuclear
A. Portu, G. Saint Martin, D. Brandizzi, O. A. Bernaola, R. L. Cabrini
APPLIED RADIATION AND ISOTOPES
(2011)
Article
Cell Biology
Maria Luisa Paparella, Liliana Graciela Olvi, Daniel Brandizzi, Alicia Keszler, Eduardo Santini-Araujo, Romulo Luis Cabrini
Article
Dentistry, Oral Surgery & Medicine
D. G. Olmedo, M. L. Paparella, D. Brandizzi, R. L. Cabrini
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
(2010)
Article
Dentistry, Oral Surgery & Medicine
Daniel G. Olmedo, Maria L. Paparella, Martin Spielberg, Daniel Brandizzi, Maria B. Guglielmotti, Romulo L. Cabrini
JOURNAL OF PERIODONTOLOGY
(2012)
Article
Dentistry, Oral Surgery & Medicine
Daniel Brandizzi, Hector Eduardo Lanfranchi, Romulo L. Cabrini
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY
(2009)
Article
Dentistry, Oral Surgery & Medicine
Daniel Brandizzi, Mariana Gandolfo, Maria Lucia Velazco, Romulo Luis Cabrini, Hector Eduardo Lanfranchi
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
(2008)
